publication venue for
- Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis.. 15. 2025
- Reproductive factors and expression of stem cell markers in women with incident benign breast disease.. 14. 2024
- Associations of stem cell markers in benign breast tissue with subsequent breast cancer risk.. 13. 2023
- Induction of resistance to oxaliplatin in cancer by a microRNA/Fem1B/Gli1 pathway.. 13. 2023
- MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy.. 12. 2022
- Chemotherapy-induced cytokines and prognostic gene signatures vary across breast and colorectal cancer.. 11. 2021
- CDKN1A/p21WAF1, RB1, ARID1A, FLG, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies.. 11. 2021
- Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations.. 11. 2021
- Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer.. 11. 2021
- Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.. 6. 2016
- TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.. 5. 2015
- Loss of function mutations in CDKN1A are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma.. 12. 2022
- Emerging role of competing endogenous RNA and associated noncoding RNAs in thyroid cancer. 2022